CureVac

Updated: January 17, 2026

Ingmar Hoerr, CEO

Country: Germany | Funding: $2.1B (+)

CureVac is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA. Acquired by BioNTech